March 27, 2017 10:09 AM EDTUpdated 11:40 AM

Erytech shares soar on positive results for PhIIb pancreatic cancer trial; ArQule’s tivantinib fails yet again in PhIII cancer study

Shehla Shakoor

Managing Director

→ France’s Erytech Pharma says it garnered positive data in a Phase IIb study of eryaspase combined with chemo for second-line metastatic pancreatic cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Erytech shares soar on positive results for PhIIb pancreatic cancer trial; ArQule’s tivantinib fails yet again in PhIII cancer study

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Ery­tech shares soar on pos­i­tive re­sults for PhI­Ib pan­cre­at­ic can­cer tri­al; Ar­Qule’s tivan­ti­nib fails yet again in PhI­II can­cer study

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

Erytech shares soar on positive results for PhIIb pancreatic cancer trial; ArQule’s tivantinib fails yet again in PhIII cancer study

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?